SteadyMed Ltd. (STDY) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results
November 12, 2015 4:17 PM ESTSAN RAMON, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced recent developments and financial results for the third quarter ended September 30, 2015.
"SteadyMed continued to make significant progress in executing across several strategic initiatives during and subsequent to the third quarter. As expected, we recently began production of registration stability lots for our lead drug product candidate Trevyent®, for the treatment of pulmonary arterial hypertension (PAH). We expect to have the... More
SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results
November 12, 2015 4:17 PM ESTSAN RAMON, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced recent developments and financial results for the third quarter ended September 30, 2015.
"SteadyMed continued to make significant progress in executing across several strategic initiatives during and subsequent to the third quarter. As expected, we recently began production of registration stability lots for our lead drug product candidate Trevyent®, for the treatment of pulmonary arterial hypertension (PAH). We expect to have the... More
